Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma

Oncology. 2004;67(5-6):471-5. doi: 10.1159/000082932.

Abstract

Hepatic epithelioid hemangioendothelioma (HEH) is a rare vascular tumor of the liver with an unpredictable malignant potential. Its growth can lead to hepatic failure, extrahepatic metastasis and death. Surgical resection or liver transplantation is the treatment of choice if metastasis is not identified. Several antineoplastic agents have been proposed for cases of nonresectable HEH. We report the case of a 52-year-old patient with HEH metastatic to the lungs who was successfully treated with oral thalidomide therapy.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Disease Progression
  • Drug Administration Schedule
  • Hemangioendothelioma, Epithelioid / diagnostic imaging
  • Hemangioendothelioma, Epithelioid / drug therapy*
  • Hemangioendothelioma, Epithelioid / pathology*
  • Humans
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology*
  • Male
  • Middle Aged
  • Thalidomide / administration & dosage
  • Thalidomide / therapeutic use*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Thalidomide